CorMedix announced $355 million in cash and reaffirmed 2026 revenue guidance of $325M-$345M, anticipating a DefenCath reimbursement increase for Q1 2027. Management indicated that Add-on projected rates in 2027 will exceed current levels.
CorMedix announced $355 million in cash and reaffirmed 2026 revenue guidance of $325M-$345M, anticipating a DefenCath reimbursement increase for Q1 2027. Management indicated that Add-on projected rates in 2027 will exceed current levels.